Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 219

1.

Prospective, randomized, controlled, and open study in primarily inoperable, stage III non-small cell lung cancer (NSCLC) patients given sequential radiochemotherapy with or without epoetin alfa.

Debus J, Drings P, Baurecht W, Angermund R.

Radiother Oncol. 2014 Jul;112(1):23-9. doi: 10.1016/j.radonc.2014.06.005. Epub 2014 Aug 13.

PMID:
25129551
2.

[Efficacy and sustainability of a smoking prevention program for pupils--"ohnekippe"].

Kreuter M, Bauer CM, Ehmann M, Kappes J, Drings P, Herth FJ.

Dtsch Med Wochenschr. 2014 Jul;139(27):1403-8. doi: 10.1055/s-0034-1370129. Epub 2014 Jun 17. German.

PMID:
24937077
3.

Single nucleotide polymorphisms in matrix metalloproteinase genes and lung cancer chemotherapy response and prognosis.

Scherf DB, Dally H, Müller P, Werle-Schneider G, Jäger B, Edler L, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A.

Eur Respir J. 2010 Feb;35(2):381-90. doi: 10.1183/09031936.00125608. Epub 2009 Jul 30.

4.

Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients.

Müller PJ, Dally H, Klappenecker CN, Edler L, Jäger B, Gerst M, Spiegelhalder B, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A.

Int J Cancer. 2009 Apr 1;124(7):1669-74. doi: 10.1002/ijc.23956.

5.

Early onset lung cancer, cigarette smoking and the SNP309 of the murine double minute-2 (MDM2) gene.

Mittelstrass K, Sauter W, Rosenberger A, Illig T, Timofeeva M, Klopp N, Dienemann H, Meese E, Sybrecht G, Woelke G, Cebulla M, Degen M, Morr H, Drings P, Groeschel A, Kreymborg KG, Haeussinger K, Hoeffken G, Schmidt C, Jilge B, Schmidt W, Ko YD, Taeuscher D, Chang-Claude J, Wichmann HE, Bickeboeller H, Risch A.

BMC Cancer. 2008 Apr 23;8:113. doi: 10.1186/1471-2407-8-113.

6.

Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years.

Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, Wölke G, Meese E, Sybrecht G, Kronenberg F, Cebulla M, Degen M, Drings P, Gröschel A, Konietzko N, Kreymborg KG, Häussinger K, Höffken G, Jilge B, Ko YD, Morr H, Schmidt C, Schmidt EW, Täuscher D, Bickeböller H, Wichmann HE.

BMC Cancer. 2008 Feb 25;8:60. doi: 10.1186/1471-2407-8-60.

8.

[The effect of haemoglobin levels on prognosis and quality of life of patients with bronchial carcinoma].

Drings P, Wannenmacher M.

Dtsch Med Wochenschr. 2005 Jun 17;130(24):1507-11. German.

PMID:
15942841
9.

Cancer-related anemia: pathogenesis, prevalence and treatment.

Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S.

Oncology. 2005;68 Suppl 1:3-11. Review.

PMID:
15855811
10.

Immunohistochemical and cytogenetic characterization of acantholytic squamous cell carcinoma of the breast.

Aulmann S, Schnabel PA, Helmchen B, Dienemann H, Drings P, Otto HF, Sinn HP.

Virchows Arch. 2005 Mar;446(3):305-9. Epub 2005 Jan 25.

PMID:
15668805
11.

[IALT Trial].

Drings P.

Internist (Berl). 2005 Feb;46(2):214-5. German. No abstract available.

PMID:
15609034
12.

Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene.

Butkiewicz D, Popanda O, Risch A, Edler L, Dienemann H, Schulz V, Kayser K, Drings P, Bartsch H, Schmezer P.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6.

13.

Data security and protection in cross-institutional electronic patient records.

van der Haak M, Wolff AC, Mludek V, Drings P, Wannenmacher M, Wetter T.

Stud Health Technol Inform. 2002;90:341-5.

PMID:
15460714
14.

Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer.

Popanda O, Schattenberg T, Phong CT, Butkiewicz D, Risch A, Edler L, Kayser K, Dienemann H, Schulz V, Drings P, Bartsch H, Schmezer P.

Carcinogenesis. 2004 Dec;25(12):2433-41. Epub 2004 Aug 27.

PMID:
15333465
15.

Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3).

Lee YM, Cui Y, König J, Risch A, Jäger B, Drings P, Bartsch H, Keppler D, Nies AT.

Pharmacogenetics. 2004 Apr;14(4):213-23.

PMID:
15083066
16.

Genotype relationships in the CYP3A locus in Caucasians.

Dally H, Bartsch H, Jäger B, Edler L, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Kayser K, Schulz V, Risch A.

Cancer Lett. 2004 Apr 15;207(1):95-9.

PMID:
15050738
17.

The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.

Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A.

Pharmacogenetics. 2003 Oct;13(10):607-18.

PMID:
14515059
18.

Data security and protection in cross-institutional electronic patient records.

van der Haak M, Wolff AC, Brandner R, Drings P, Wannenmacher M, Wetter T.

Int J Med Inform. 2003 Jul;70(2-3):117-30.

PMID:
12909163
19.

Technical performance and diagnostic utility of the new Elecsys neuron-specific enolase enzyme immunoassay.

Muley T, Ebert W, Stieber P, Raith H, Holdenrieder S, Nagel D, Fürst H, Roth HJ, Luthe H, Blijenberg BG, Gurr E, Uhl W, von Pawel J, Drings P.

Clin Chem Lab Med. 2003 Jan;41(1):95-103.

PMID:
12636057
20.

Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking.

Godschalk R, Nair J, van Schooten FJ, Risch A, Drings P, Kayser K, Dienemann H, Bartsch H.

Carcinogenesis. 2002 Dec;23(12):2081-6.

PMID:
12507931
21.

Networking in shared care--first steps towards a shared electronic patient record for cancer patients.

van der Haak M, Mludek V, Wolff AC, Bülzebruck H, Oetzel D, Zierhut D, Drings P, Wannenmacher M, Haux R.

Methods Inf Med. 2002;41(5):419-25.

PMID:
12501815
22.

Myeloperoxidase (MPO) genotype and lung cancer histologic types: the MPO -463 A allele is associated with reduced risk for small cell lung cancer in smokers.

Dally H, Gassner K, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Drings P, Dienemann H, Schulz V, Kayser K, Bartsch H, Risch A.

Int J Cancer. 2002 Dec 10;102(5):530-5.

23.

Comparison of changes in the NSE levels with clinical assessment in the therapy monitoring of patients with SCLC.

Ebert W, Muley T, Trainer C, Dienemann H, Drings P.

Anticancer Res. 2002 Mar-Apr;22(2B):1083-9.

PMID:
12168905
24.

Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001.

Fischer JR, Baas P, Becker HD, Chyczewski L, Dienemann H, Drings P, Ebert W, Herth F, Hoffmann H, Laudanski J, Lahm H, Manegold Ch, Monzó M, Mooi WJ, Muley T, Neuner A, Niklinski J, Niklinska W, Rosell R, Taron M, van't Veer L, Werle B, Zandwijk Nv.

Lung Cancer. 2002 May;36(2):221-4. No abstract available.

PMID:
11955661
25.

Glutathione-S-transferase M1, M3, T1 and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas.

Risch A, Wikman H, Thiel S, Schmezer P, Edler L, Drings P, Dienemann H, Kayser K, Schulz V, Spiegelhalder B, Bartsch H.

Pharmacogenetics. 2001 Dec;11(9):757-64.

PMID:
11740339
26.

Using the eXtensible Markup Language (XML) in a regional electronic patient record for patients with malignant diseases.

Wolff AC, Mludek V, van der Haak M, Bork W, Bülzebruck H, Drings P, Schmücker P, Wannenmacher M, Haux R.

Stud Health Technol Inform. 2001;84(Pt 1):698-702.

PMID:
11604828
27.

Integration of clinical practice guidelines into a distributed regional electronic patient record for tumour-patients using XML: a means for standardization of the treatment processes.

Mludek V, Wolff AC, Drings P, van der Haak M, Haux R, Wannenmacher M, Zierhut D.

Stud Health Technol Inform. 2001;84(Pt 1):658-62.

PMID:
11604819
28.

[Immunobiology of the non-small-cell lung carcinoma: new aspects].

Fischer JR, Neuner A, Muley T, Lahm H, Drings P.

Onkologie. 2001 Sep;24 Suppl 5:72-4. German. No abstract available.

PMID:
11600817
29.

Endobronchial ultrasound (EBUS)--assessment of a new diagnostic tool in bronchoscopy for staging of lung cancer.

Herth F, Becker HD, Manegold C, Drings P.

Onkologie. 2001 Apr;24(2):151-4.

PMID:
11441295
30.

Sensitive detection of rare cancer cells in sputum and peripheral blood samples of patients with lung cancer by preproGRP-specific RT-PCR.

Lacroix J, Becker HD, Woerner SM, Rittgen W, Drings P, von Knebel Doeberitz M.

Int J Cancer. 2001 Apr 1;92(1):1-8.

31.

Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility.

Wikman H, Thiel S, Jäger B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H, Risch A.

Pharmacogenetics. 2001 Mar;11(2):157-68.

PMID:
11266080
32.

Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer.

Rajaee-Behbahani N, Schmezer P, Risch A, Rittgen W, Kayser KW, Dienemann H, Schulz V, Drings P, Thiel S, Bartsch H.

Int J Cancer. 2001 Mar 20;95(2):86-91.

33.

[Differential indications for induction therapy of non-small-cell lung tumors].

Drings P, Manegold C.

Chirurg. 2000 Dec;71(12):1466-73. Review. German.

PMID:
11195065
34.

Long-term survival in small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis.

Fischer JR, Schindel M, Bülzebruck H, Lahm H, Krammer PH, Drings P.

J Cancer Res Clin Oncol. 2000 Dec;126(12):730-3.

PMID:
11153147
35.

Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes.

Schmezer P, Rajaee-Behbahani N, Risch A, Thiel S, Rittgen W, Drings P, Dienemann H, Kayser KW, Schulz V, Bartsch H.

Mutagenesis. 2001 Jan;16(1):25-30.

PMID:
11139596
36.

hOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a caucasian population.

Wikman H, Risch A, Klimek F, Schmezer P, Spiegelhalder B, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H.

Int J Cancer. 2000 Dec 15;88(6):932-7.

37.

Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.

Gatzemeier U, Kleisbauer JP, Drings P, Kaukel E, Samaras N, Melo MJ, Cardenal F, Robinet G, Snijder RJ, von Pawel J, Palisses R.

Am J Clin Oncol. 2000 Aug;23(4):393-400.

PMID:
10955871
38.

Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG).

Sessa C, Wanders J, Roelvink M, Dombernowsky P, Nielsen D, Morant R, Drings P, Wissel P, Hanauske AR.

Ann Oncol. 2000 Feb;11(2):207-10.

PMID:
10761757
39.

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.

ten Bokkel Huinink WW, Bergman B, Chemaissani A, Dornoff W, Drings P, Kellokumpu-Lehtinen PL, Liippo K, Mattson K, von Pawel J, Ricci S, Sederholm C, Stahel RA, Wagenius G, Walree NV, Manegold C.

Lung Cancer. 1999 Nov;26(2):85-94.

PMID:
10568679
40.

Coping, distress, and survival among patients with lung cancer.

Faller H, Bülzebruck H, Drings P, Lang H.

Arch Gen Psychiatry. 1999 Aug;56(8):756-62.

PMID:
10435611
41.

Dyspnea in cancer patients.

Drings P.

Support Care Cancer. 1999 Jul;7(4):215-6. Review. No abstract available.

PMID:
10423043
42.

Ifosfamide and docetaxel in non-small cell lung cancer.

Drings P, Büchholz E, Manegold C.

Semin Oncol. 1998 Feb;25(1 Suppl 2):29-37. Review.

PMID:
9535209
43.

Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer.

Gatzemeier U, Manegold C, Eberhard W, Wilke HJ, Chomy F, Chomy P, Khayat D, Blatter J, Seeber S, Drings P.

Semin Oncol. 1998 Feb;25(1 Suppl 2):15-8.

PMID:
9535206
44.

Role of vindesine in induction chemotherapy in locally-advanced non-small-cell lung cancer.

Fischer JR, Drings P.

J Cancer Res Clin Oncol. 1998 Jan;124(1):4-9. Review.

PMID:
9498828
45.

Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.

Volm M, Rittgen W, Drings P.

Br J Cancer. 1998 Feb;77(4):663-9. Erratum in: Br J Cancer 1998 Apr;77(7):1198.

46.
47.
48.

Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.

Ebert W, Hoppe M, Muley T, Drings P.

Anticancer Res. 1997 Jul-Aug;17(4B):2875-8.

PMID:
9329552
49.

[Pneumonitis after radiotherapy of bronchial carcinoma: incidence and influencing factors].

Schraube P, Schell R, Wannenmacher M, Drings P, Flentje M.

Strahlenther Onkol. 1997 Jul;173(7):369-78. German.

PMID:
9265259
50.

[Do psychological factors modify survival of cancer patients? II: Results of an empirical study with bronchial carcinoma patients].

Faller H, Bülzebruck H, Schilling S, Drings P, Lang H.

Psychother Psychosom Med Psychol. 1997 Jun;47(6):206-18. German.

PMID:
9333831

Supplemental Content

Loading ...
Support Center